| HLA-haploidentical stem cell transplantation in children with inherited bone marrow failure syndromes: A retrospective analysis on behalf of EBMT severe aplastic Anemia and pediatric diseases working parties |
|
American Journal of Hematology |
Aplastic Anemia |
| Massive hemolysis in paroxysmal nocturnal hemoglobinuria after switching from proximal complement inhibitor to anti-C5 therapy: A lesson not to be forgotten |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| The Importance of Controlling Terminal Complement Activity and Intravascular Hemolysis in Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Luspatercept use for lower risk myelodysplastic syndromes: Active but not enough |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study |
|
American Journal of Hematology |
Aplastic Anemia |
| Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study |
|
American Journal of Hematology |
Aplastic Anemia |
| Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
